Samrat Pharmachem (SAMRATPH) | Stock Overview & Key Data
Samrat Pharmachem Performance Comparison
Stock Range
Today's Range
Low: ₹318.00
High: ₹325.95
on August 20, 2025
52 Week Range
Low: ₹302.05
High: ₹646.00
on April 7, 2025
on September 18, 2024
All-Time High: ₹1,250.00 on September 19, 2022
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Market Cap
INR982.4M
EPS
23.02
P/E Ratio (TTM)
13.81
Forward P/E
N/A
P/B Ratio
1.37
PEG Ratio
N/A
Div. Yield
0.29%
ROE
9.91%
Beta
-0.321
Debt to Equity
13.81
Financial Highlights
Profitability
Gross Margin
3.39%
Operating Margin
-0.06%
Profit Margin
1.72%
Returns and Earnings
Return on Assets (TTM)
5.85%
Return on Equity (TTM)
9.91%
EBITDA
INR112.1M
Net Income (TTM)
INR48.2M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
INR908.46
Quarterly Revenue Growth (YoY)
-6.40%
Quarterly Earnings Growth (YoY)
-13.88%
Dividend Information
Last 12-Month Dividend
₹1.00
Current Dividend Yield
0.29%
3-Year Average Dividend Yield
0.17%
3-Year Average Annual Dividend
₹1.67
3-Year Total Dividends
₹5.00
Ex-Dividend Date
September 19, 2024
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Samrat Pharmachem SAMRATPH | 982.37M Small-cap | -6.16% | -12.87% | -14.81% | -11.45% | -17.63% | -30.15% | -57.38% | 181.12% |
| Navin Fluorine NAVINFLUOR | 255.94B Large-cap | 2.76% | 1.23% | 16.74% | 24.39% | 53.36% | 52.80% | 19.25% | 135.76% |
| Deepak Nitrite DEEPAKNTR | 246.94B Large-cap | -2.71% | -6.35% | -14.39% | -5.19% | -27.40% | -35.71% | -7.50% | 142.52% |
| India Glycols INDIAGLYCO | 55.32B Mid-cap | 0.36% | -5.84% | 0.31% | 48.69% | 33.21% | 35.55% | 91.92% | 457.17% |
| Styrenix Performance STYRENIX | 46.38B Small-cap | -2.72% | -15.60% | -9.75% | 7.41% | -12.44% | -3.65% | 188.91% | 407.99% |
| Gujarat Alkalies GUJALKALI | 41.50B Small-cap | -0.09% | -4.89% | -14.86% | -2.74% | -25.13% | -27.60% | -37.68% | 48.00% |
Ownership & Short Interest
Insider Ownership
59.26%
Institutional Ownership
0.00%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
2K
Average 90-Day Volume
3K
Samrat Pharmachem Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Samrat Pharmachem would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is SAMRATPH's 52-week high and low?
- In the last 52 weeks, Samrat Pharmachem reached a high of ₹646.00 (on September 18, 2024) and a low of ₹302.05 (on April 7, 2025).
- What is the market cap and P/E ratio for SAMRATPH?
- Curious about Samrat Pharmachem's size and valuation? Its market capitalization stands at 982.37M. When it comes to valuation, the P/E ratio (trailing twelve months) is 13.81, and the forward P/E (looking ahead) is N/A.
- Does SAMRATPH pay dividends? If so, what's the yield?
- Yes, Samrat Pharmachem is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.29%, and the company has paid an average of ₹1.67 per share annually over the past 3 years.
- Who are Samrat Pharmachem's main competitors or similar companies to consider before investing?
When looking at Samrat Pharmachem, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Navin Fluorine
NAVINFLUOR255.94B Basic Materials Chemicals 52.80% 19.25% Deepak Nitrite
DEEPAKNTR246.94B Basic Materials Chemicals -35.71% -7.50% India Glycols
INDIAGLYCO55.32B Basic Materials Chemicals 35.55% 91.92% Styrenix Performance
STYRENIX46.38B Basic Materials Chemicals -3.65% 188.91% Gujarat Alkalies
GUJALKALI41.50B Basic Materials Chemicals -27.60% -37.68% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Samrat Pharmachem Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Samrat Pharmachem's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 9.91%, the Debt to Equity ratio from the most recent quarter is 13.81, and its Gross Profit Margin stands at 3.39%.
- What is the recent revenue and earnings growth for SAMRATPH?
- Looking at Samrat Pharmachem's growth, its revenue over the trailing twelve months (TTM) was INR3B. Compared to the same quarter last year (YoY), quarterly revenue grew by -6.40%, and quarterly earnings saw a YoY growth of -13.88%.
- How much of SAMRATPH stock is held by insiders and institutions?
- Wondering who owns Samrat Pharmachem stock? Company insiders (like executives and directors) hold about 59.26% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 0.00%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.